Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer

Güler, Elif

doi:10.5152/ejbh.2017.3636

Cited by 51 publications

(35 citation statements)

References 48 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumour size was significantly larger in the Chinese cohort (30.9 vs. 18.1 mm), as well as the rate of lymph node metastatic involvement (54.5 vs. 27.4%). Tumour size and lymph node status still remain the most important prognostic factors in breast cancer [28][29][30]. In addition, Her-2-positive tumours and tumour proliferative index > 20% were observed more frequently among Chinese women.…”

Section: Discussionmentioning

confidence: 99%

Comparing Clinicopathologic Features and Surgical Treatment of Premenopausal Breast Cancer across Italy and China: Report from a Medical Exchange Program

Fancellu

Zhao²,

Cottu

et al. 2020

Breast Care

View full text Add to dashboard Cite

Background: This study investigated the differences in clinicopathologic features and surgical treatment between an Italian and a Chinese cohort of premenopausal women with breast cancer, and highlighted the potential advantages of international medical exchange projects. Methods: Premenopausal women who underwent surgical treatment between 2012 and 2016 at one Italian and one Chinese institution participating in a medical exchange program were compared. Factors associated with the probability to receive mastectomy were determined via logistic analysis. Changes in surgical management at the Chinese institution in the period 2018–2019, after the exchange program, were also evaluated. Results: A total of 505 patients, 318 from Italy and 187 from China, were evaluated. The Chinese patients had more frequently advanced-stage tumours, large tumour size (30.9 vs. 18.1 mm, p < 0.01), invasive carcinoma (92.5 vs. 83.3%, p < 0.01), positive axillary lymph nodes (54.5 vs. 27.4%, p < 0.01), Her-2 positivity (36.4 vs. 22.0%, p < 0.01), and high proliferative index (55.1 vs. 30.2%, p < 0.01). Positive oestrogen receptor status and rates of triple-negative breast cancer did not differ (77.0 vs. 69.5%, p = 0.09 and 14.2 vs. 16%, p = 0.56, respectively). Mastectomy rates were higher among Chinese women (85 vs. 41%, p < 0.001), whereas use of sentinel node biopsy was more frequent among Italian women (77 vs. 33%, p < 0.001). Chinese women had more than 4-fold higher risk of receiving mastectomy. In the last 2 years, the rates of breast-conserving surgery and sentinel node biopsy at the Chinese institution increased from 15 to 23%, and from 33 to 42%, respectively. Conclusions: Tumour features and surgical strategies for premenopausal breast cancer may differ signiﬁcantly between Italy and China. Since the international exchange program, patients from the Chinese institution have been offered more frequently less invasive surgery. International exchange programs can help in designing epidemiological studies which may be useful for strategies to improve breast cancer management and control.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparing Clinicopathologic Features and Surgical Treatment of Premenopausal Breast Cancer across Italy and China: Report from a Medical Exchange Program

Fancellu

Zhao²,

Cottu

et al. 2020

Breast Care

View full text Add to dashboard Cite

show abstract

“…The description of different molecular subtypes based on DNA microarray and their prognostic significance has led to wide acceptance of these subgroups in clinical practice. [ 5 6 ] The use of DNA microarray technology has not gained widespread acceptance in routine clinical practice and immunohistochemistry (IHC) is often used as a surrogate marker to define these molecular subtypes. [ 7 ]…”

Section: Introductionmentioning

confidence: 99%

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography features in locally advanced breast cancer and their correlation with molecular subtypes

et al. 2018

View full text Add to dashboard Cite

Purpose:18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is now recognized as a staging investigation for locally advanced breast cancer. This retrospective review of data was performed to correlate the maximum standardized uptake value (SUVmax) of the primary tumor with the molecular subtype of breast cancer.Materials and Methods:Patients with biopsy-proven, treatment naïve, Stage III breast cancer, for whom 18F-FDG PET/CT data and immunohistochemistry 4 was available were included in the study. Correlations were deduced between the SUVmax of primary tumor to the molecular subtypes.Results:Three hundred and two patients were included in the study. Fifty-two (17.2%) tumors were Luminal A (LA), 131 (43.4%) Luminal B (LB), 42 (13.9%) human epidermal growth factor receptor-2 enriched (HE), and 77 (25.5%) basal-like (BL). SUVmax of the primary tumor differed significantly between LA and other subtypes (SUVmax: LA Median 7.4, LB 11.65, HE 13.5, BL 15.35, P < 0.001). Estrogen receptor (ER) and progesterone receptor (PR) positivity were inversely correlated to the SUVmax of the primary (SUVmax: ER + Median 10.4, ER - 14.2, P < 0.001, PR + 9.65, PR − 13.9, P < 0.001). There was a strong positive correlation observed between Ki67 and SUVmax (Pearson Coefficient 0.408, P < 0.001). A SUVmax value of 9.65 was determined as a cutoff on receiver operating characteristic curve to differentiate between LA and other subtypes with a sensitivity of 92.3% and specificity of 70.6%.Conclusions:SUVmax of primary showed a statistically significant difference between LA subtypes when compared to other subtypes. However, there was overlap of values in each subgroup and thus 18F-FDG PET/CT cannot be used to accurately assess the molecular characteristics of the tumor.

show abstract

“…There are three main clinically relevant biological subtypes: Oestrogen/Progesterone receptor positive breast cancer (ER + /PR + ), HER2 amplified (HER2 + ) breast cancer and Triple Negative Breast Cancer (TNBC; i.e., ER -, PR -, HER2 -) [21][22][23] . Based on gene expression signatures four main molecular subtypes have been reported: Luminal A and B, HER2 + , and basal-like, which overlap largely, but not fully with the ER + /PR+; HER2 + and TNBC biological subtypes, respectively [24,25] . Both biological and molecular classifications have prognostic and predictive (therapeutic) relevance [19,20,24,25] : ER + tumors are treated with adjuvant anti-estrogen therapies (e.g., tamoxifen) while HER2 + tumors are treated with HER2 inhibitors (e.g., trastuzumab), in addition to radiotherapy and chemotherapy, if necessary [19,26] .…”

Section: Breast Cancer Subtypes and Adjuvant Therapiesmentioning

confidence: 99%

“…Based on gene expression signatures four main molecular subtypes have been reported: Luminal A and B, HER2 + , and basal-like, which overlap largely, but not fully with the ER + /PR+; HER2 + and TNBC biological subtypes, respectively [24,25] . Both biological and molecular classifications have prognostic and predictive (therapeutic) relevance [19,20,24,25] : ER + tumors are treated with adjuvant anti-estrogen therapies (e.g., tamoxifen) while HER2 + tumors are treated with HER2 inhibitors (e.g., trastuzumab), in addition to radiotherapy and chemotherapy, if necessary [19,26] . TNBC, has no molecular target useful for targeted therapy yet and adjuvant radio-and chemotherapies are still the standards of care [22,27] .…”

Section: Breast Cancer Subtypes and Adjuvant Therapiesmentioning

confidence: 99%

Chemotherapy-induced immunological breast cancer dormancy: a new function for old drugs?

Peyvandi¹,

Lan²,

Lorusso³

et al. 2019

JCMT

View full text Add to dashboard Cite

Breast cancer remains the main cause of cancer-related mortality for women worldwide. Main cause of death is the development of therapy-resistant metastases. Relapses occur with a bimodal temporal distribution, with a first peak at 1-2 years after initial therapy and a second peak 2-3 years later. This discontinuous growth kinetics is consistent with the notion that disseminated cancer cells can remain dormant over a prolonged period of time before resuming growth. How cancer cells enter, sustain and exit dormancy, are unanswered questions with relevance to cancer biology, monitoring and therapy. Investigating mechanisms of breast cancer dormancy remains challenging, as in patients the condition is elusive and experimentally there are only a few models that recapitulate the clinical condition. Thus, developing new models to identify clinically relevant mechanisms and candidate therapeutic targets may open new avenues for novel therapies to induce and prolong dormancy. We have observed that cells surviving chemotherapy can enter a state of immunological dormancy. Using this model, we identified IRF-7/Interferon type I/IFNRA as signaling axis essential for this effect. Here we will review concepts and recent developments in cancer metastasis and dormancy with emphasis on breast cancer, and elaborate strategies to exploit them therapeutically.

show abstract

Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer

Cited by 51 publications

References 48 publications

Comparing Clinicopathologic Features and Surgical Treatment of Premenopausal Breast Cancer across Italy and China: Report from a Medical Exchange Program

Comparing Clinicopathologic Features and Surgical Treatment of Premenopausal Breast Cancer across Italy and China: Report from a Medical Exchange Program

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography features in locally advanced breast cancer and their correlation with molecular subtypes

Chemotherapy-induced immunological breast cancer dormancy: a new function for old drugs?

Contact Info

Product

Resources

About

Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer

Cited by 51 publications

References 48 publications

Comparing Clinicopathologic Features and Surgical Treatment of Premenopausal Breast Cancer across Italy and China: Report from a Medical Exchange Program

Comparing Clinicopathologic Features and Surgical Treatment of Premenopausal Breast Cancer across Italy and China: Report from a Medical Exchange Program

18F-fluorodeoxyglucose positron emission tomography/computed tomography features in locally advanced breast cancer and their correlation with molecular subtypes

Chemotherapy-induced immunological breast cancer dormancy: a new function for old drugs?

Contact Info

Product

Resources

About

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography features in locally advanced breast cancer and their correlation with molecular subtypes